Table 1.
Demographics and clinical characteristics.
| Demographics and Clinical Characteristics | All Participants (n = 33) |
MedDiet (n = 23) |
Usual Care (n = 10) |
|---|---|---|---|
| Age (years, mean ± SD) | 51.0 ± 14.6 | 51.7 ± 14.2 | 49.2 ± 16.3 |
| Gender, n (%) | |||
| Male | 2 (6.1%) | 2 (8.7%) | 0 |
| Female | 31 (93.9%) | 21 (91.3%) | 10 (100%) |
| Race and Ethnicity, n (%) | |||
| Asian | 2 (6.1%) | 2 (8.7%) | 0 |
| Black/African American | 2 (6.1%) | 1 (4.3%) | 1 (10%) |
| Hispanic, any race | 0 | 0 | 0 |
| White, Non-Hispanic | 29 (87.9%) | 20 (87.0%) | 9 (90%) |
| Marital status, n (%) | |||
| Married or long-term significant other | 25 (75.8%) | 18 (78.3%) | 7 (70%) |
| Divorced, separated, single, or widowed | 8 (24.2%) | 5 (21.7%) | 3 (30%) |
| Employment, n (%) | |||
| Employed (including self-employed) | 20 (60.6%) | 13 (56.5%) | 7 (70%) |
| Homemaker, unemployed, or retired | 13 (39.4%) | 10 (43.5%) | 3 (30%) |
| Highest level of education, n (%) | |||
| Less than a high school degree | 0 | 0 | 0 |
| High school/GED | 3 (9.1%) | 1 (4.3%) | 2 (20%) |
| 2- or 4-year degree or some college | 16 (48.5%) | 11 (47.8%) | 5 (50%) |
| Graduate degree | 14 (42.4%) | 11 (47.8%) | 3 (30%) |
| Body mass index (kg/m2, mean ± SD) | 29.4 ± 6.8 | 28.9 ± 6.1 | 30.5 ± 8.5 |
| Type of cancer, n (%) | |||
| Breast | 30 (90.9%) | 20 (87.0%) | 10 (100%) |
| Other | 3 (9.1%) | 3 (13.0%) | 0 |
| Cancer stage, n (%) | |||
| Stage 1 | 8 (24.2%) | 4 (17.4%) | 4 (40%) |
| Stage 2 | 21 (63.6%) | 17 (73.9%) | 4 (40%) |
| Stage 3 | 2 (6.1%) | 1 (4.3%) | 1 (10%) |
| Other or Unknown | 2 (6.1%) | 1 (4.3%) | 1 (10%) |
| Previous treatment for cancer, n (%) | |||
| Surgery | 15 (45.5%) | 11 (47.8%) | 4 (40%) |
| Chemotherapy | 1 (3.0%) | 1 (4.3%) | 0 |
| Radiation | 1 (3.0%) | 1 (4.3%) | 0 |
| Place in treatment at baseline, n (%) | |||
| Had begun chemotherapy | 25 (76%) | 17 (74%) | 8 (80%) |
| Chemotherapy-naïve | 8 (24%) | 6 (26%) | 2 (20%) |
| Type of chemotherapy, n (%) | |||
| Doxorubicin Cyclophosphamide (AC) * | 11 (33.3%) | 7 (30.4%) | 4 (40%) |
| Paclitaxel (with or without Trastuzumab) | 7 (21.3%) | 4 (17.4%) | 3 (30%) |
| Docetaxel Cyclophosphamide (TC) | 4 (12.1%) | 2 (8.7%) | 2 (20%) |
| Docetaxel Carboplatin Trastuzumab Pertuzumab (TCHP) | 7 (21.2%) | 6 (26.1%) | 1 (10%) |
| Other (all non-anthracycline) | 4 (12.1%) | 4 (17.4%) | 0 |
* Sometimes followed by taxane-based chemotherapy with or without targeted therapy.